Prevent Pandemics Act: Key Provisions, Legislative Status & Impact

Table of Contents#

1. What is the Prevent Pandemics Act?
2. Key Provisions of the Act
   • Enhanced Surveillance and Early Detection
   • Investment in Research and Innovation
   • Strengthening Public Health Infrastructure
   • Global Health Collaboration
   • ARPA-H Authorization
   • Structural Leadership Reforms
3. Legislative History and Enactment
   • Introduction and Bipartisan Support
   • Signing into Law
4. Implementation Challenges and Criticisms
5. Conclusion
6. References

What is the Prevent Pandemics Act?#

The Prevent Pandemics Act is a federal law designed to address systemic weaknesses in pandemic preparedness identified during COVID-19. Its primary goal is to shift the U.S. from a reactive "response" mindset to a proactive "prevention" strategy by investing in early detection, scientific research, public health infrastructure, and global collaboration. Introduced as S. 3799 in the 117th Congress, the Act passed the Senate Health, Education, Labor, and Pensions (HELP) Committee by a vote of 20-2 on March 15, 2022, and was subsequently incorporated into the Consolidated Appropriations Act, 2023. It was signed into law by President Biden on December 29, 2022.

Key Provisions of the Act#

The Act outlines several critical provisions to strengthen pandemic preparedness. Below is a detailed breakdown of its core components:

Enhanced Surveillance and Early Detection#

Early detection is critical to containing outbreaks. The Act proposes:

• Modernizing Disease Surveillance Systems: Updating outdated public health data systems to integrate real-time data from hospitals, labs, and community health centers. This includes funding for tools like electronic health records (EHRs) and AI-driven analytics to spot emerging threats faster.
• Expanding "One Health" Approach: Recognizing that human, animal, and environmental health are interconnected, the Act mandates collaboration between the Centers for Disease Control and Prevention (CDC), the Department of Agriculture (USDA), and the Environmental Protection Agency (EPA) to monitor zoonotic diseases (e.g., COVID-19, avian flu) at the animal-human interface.
• Genomic Sequencing and Pathogen Genomics: The Act authorizes grants for the establishment of centers of excellence in pathogen genomics and molecular epidemiology to improve detection and response to pathogens that may cause public health emergencies.
• Privacy Protections: Balancing surveillance with civil liberties by requiring transparency in data collection and limiting access to personal health information to authorized public health officials.

Investment in Research and Innovation#

To stay ahead of novel pathogens, the Act prioritizes research into vaccines, therapeutics, and diagnostics:

• Pandemic Potential Pathogens: Funding for the National Institutes of Health (NIH) to study "high-risk" pathogens (e.g., coronaviruses, influenza) with pandemic potential, including gain-of-function research (controversial but critical for understanding virulence). The Act also includes restrictions on research on potential pandemic pathogens at foreign institutions in countries of concern.
• Rapid Vaccine Development: Establishing frameworks to streamline the development and manufacturing of vaccines for emerging threats, reducing timelines from years to months (as seen with COVID-19 mRNA vaccines). The Act also accelerates countermeasure development and review during declared emergencies.
• Therapeutic Stockpiles: Requiring the Department of Health and Human Services (HHS) to maintain and modernize the Strategic National Stockpile (SNS) of antiviral drugs, monoclonal antibodies, masks, vaccines, tests, and other treatments to deploy during outbreaks. The law requires the Secretary to report to Congress on the state of the SNS and issue guidance on how states, territories, and Tribes can access it.
• Diagnostic Test Development: Authorizing the Secretary of HHS to contract with public and private entities to accelerate the rapid development, validation, and dissemination of diagnostic tests during public health emergencies.
• Warm Base Manufacturing: Authorizing the Biomedical Advanced Research and Development Authority (BARDA) to support, maintain, and improve domestic manufacturing surge capacity for medical countermeasures.

Strengthening Public Health Infrastructure#

COVID-19 revealed gaps in local and state public health systems. The Act addresses this by:

• Funding for State and Local Health Departments: Authorizing grants to modernize public health labs, hire more epidemiologists and contact tracers, and train healthcare workers in pandemic response.
• Hospital Preparedness: Requiring hospitals to develop surge capacity plans (e.g., extra beds, ventilators) and conduct regular drills to test readiness for large-scale outbreaks.
• Workforce Development: Reauthorizing and improving the Public Health Workforce Loan Repayment Program to help expand the public health workforce at state, local, and tribal levels. The Act also establishes a Bio-Preparedness Workforce Pilot Program providing loan repayment for health professionals with expertise in infectious diseases and emergency preparedness.
• Centers for Public Health Preparedness and Response: Authorizing grants to institutions of higher education and nonprofit entities to establish or maintain a network of centers focused on public health preparedness.

Global Health Collaboration#

Pandemics do not respect borders. The Act emphasizes:

• Support for Low-Income Countries: Providing funding to the World Health Organization (WHO) and other global partners to build public health capacity in regions with high pandemic risk (e.g., Southeast Asia, sub-Saharan Africa). This includes training local scientists, improving lab infrastructure, and supporting disease surveillance.
• International Data Sharing: Mandating the U.S. to share outbreak data with global partners to enable coordinated responses, while also requiring other countries to report emerging threats promptly.
• U.S. Pandemic Fund Contribution: In July 2024, the United States announced a planned contribution of up to $667 million to the Pandemic Fund through 2026, supporting global pandemic prevention efforts.

ARPA-H Authorization#

One of the Act's most significant provisions is the authorization of the Advanced Research Projects Agency for Health (ARPA-H) within the NIH. ARPA-H is charged with fostering transformative innovation in biomedical science that cannot be readily accomplished through traditional federal research programs. Key details include:

• Director appointed by the President for a four-year term, reporting to the NIH Director.
• $500 million authorized for each of fiscal years 2024 through 2028.
• ARPA-H headquarters and facilities shall not be located on existing NIH campuses and must operate in at least three geographic areas.
• Focus on high-risk, high-reward research projects that have been unsuccessful in obtaining private sector funding.

Structural Leadership Reforms#

The Act enacted several structural changes to improve accountability and coordination:

• CDC Director Senate Confirmation: The CDC Director is now a Senate-confirmed position (previously appointed by the President without Senate confirmation) and must issue a strategic plan within one year of enactment, and at least every four years thereafter.
• Office of Pandemic Preparedness and Response Policy: Established within the Executive Office of the President, headed by a Director situated within both the Domestic Policy Council and National Security Council. The Director advises on policy related to pandemic preparedness and biological threats.
• COVID-19 Task Force: The Act established a task force to examine the origins of COVID-19 and the nation's response at federal, state, and local levels, making recommendations to the Administration and Congress.
• Regular Congressional Reporting: The CDC Director and the Assistant Secretary for Preparedness and Response (ASPR) are required to regularly testify before the Senate HELP Committee and House Energy and Commerce Committee on their preparedness and response activities.

Legislative History and Enactment#

Introduction and Bipartisan Support#

The Prevent Pandemics Act was first introduced in the 117th Congress (2021-2022) as S. 3799 with bipartisan support. Sponsored by Senate HELP Committee Chair Patty Murray (D-WA) and Ranking Member Richard Burr (R-NC), the bill incorporated ideas from 41 bills and 35 different members on both sides of the aisle. The Committee voted 20-2 to advance the bill on March 15, 2022, with Senators Rand Paul (R-KY) and Mike Braun (R-IN) voting against it.

Signing into Law#

Rather than proceeding as standalone legislation, significant portions of the PREVENT Pandemics Act were incorporated into the Consolidated Appropriations Act, 2023 (H.R. 2617), a year-end government funding bill. President Biden signed the omnibus package into law on December 29, 2022, as P.L. 117-328. Key provisions enacted include those related to ARPA-H authorization, CDC Director confirmation, supply chain strengthening, public health workforce expansion, and domestic manufacturing of medical supplies and generic medicines. For the full text of the enacted law, see Congress.gov - P.L. 117-328.

Implementation Challenges and Criticisms#

While the Act is now law, implementation faces ongoing challenges:

• Funding Sustainability: Although the Act authorizes significant programs, actual appropriations may differ from authorization levels. Critics question whether Congress will maintain long-term funding for infrastructure and research. ARPA-H, for example, was authorized at $500 million annually through 2028, but annual appropriations determine actual spending.
• Government Overreach Concerns: Some argue expanded surveillance could infringe on privacy, though the Act includes safeguards. Debates over the role of the federal government in public health (e.g., states' rights vs. federal mandates) continue.
• Gain-of-Function Research Concerns: Critics worry that funding for high-risk pathogen research could accidentally release dangerous viruses, though proponents argue strict safety protocols mitigate this risk. The Act includes restrictions on such research at foreign institutions in countries of concern.
• Implementation Delays: Even with authorization, modernizing systems, training workforces, and standing up new offices and programs takes time. The CDC strategic plan was due within one year of enactment.
• PAHPA Reauthorization: The Act's enactment ahead of the expiration of the Pandemic and All-Hazards Preparedness Act (PAHPA) raised questions about how the two frameworks would interact, with PAHPA reauthorization expected to be a focus of subsequent Congresses.

Conclusion#

The Prevent Pandemics Act represents a critical step toward a more proactive approach to infectious disease threats. Signed into law in December 2022, it addresses surveillance, research, infrastructure, and global collaboration with the aim of preventing the next pandemic rather than merely responding to it. By establishing ARPA-H, requiring Senate confirmation of the CDC Director, creating a White House pandemic preparedness office, and strengthening the Strategic National Stockpile, the Act lays the groundwork for a more resilient public health system. While implementation challenges remain, its bipartisan roots and evidence-based provisions offer a foundation for continued progress. As citizens, staying informed and advocating for robust pandemic preparedness funding is key to ensuring this legislation achieves its full potential.

References#

• Akin Gump Strauss Hauer & Feld LLP. (2023). Preparedness Policy Takes Shape: PREVENT Pandemics Act Enacted Ahead of PAHPA Reauthorization. akingump.com
• Cutler, D. M., & Summers, L. H. (2020). The COVID-19 Pandemic and the $16 Trillion Virus. JAMA, 324(15), 1495-1496. jamanetwork.com
• Senate Health, Education, Labor, and Pensions Committee. (2022). S. 3799, PREVENT Pandemics Act - Executive Session. help.senate.gov
• U.S. Congress. (2022). S.3799 - PREVENT Pandemics Act, 117th Congress. congress.gov
• U.S. Congress. (2022). Consolidated Appropriations Act, 2023 (P.L. 117-328). congress.gov
• U.S. Senator Susan Collins. (2023). PREVENT Pandemics Act Provisions Authored by Senator Collins Signed into Law. collins.senate.gov
• U.S. Treasury Department. (2024). United States Announces Up to $667 Million Planned Contribution to the Pandemic Fund. treasury.gov